Novel Therapies for Aggressive B-Cell Lymphoma

Table 7

Overview of ongoing or recently completed phase III studies mentioned in this paper, with agents in clinical development for the treatment of aggressive NHL. [B: bendamustine; CR: complete response; DLBCL: diffuse large B-cell lymphoma; F: fludarabine; MCL: mantle cell lymphoma; NA: not applicable; NHL: non-Hodgkin lymphoma; PFS: progression-free survival; R-CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone plus rituximab; R: rituximab; R/R: relapsed or refractory; SCT: stem cell transplantation.]

Drug	Indication	Study identifier	Study status	Results
Enzastaurin	DLBCL in remission after R-CHOP treatment	NCT00332202 PRELUDE	Ongoing; not recruiting	NA
Inotuzumab ozogamicin + R versus investigator's choice of gemcitabine + R or B + R	R/R aggressive NHL	NCT01232556	Recruiting	NA
B + R versus F + R [41]	R/R follicular, indolent, and MCL	NCT01456351	Completed; final results presented at ASH 10	B + R had better efficacy than F + R
B + R versus R-CHOP [42]	Previously untreated follicular, indolent, and MCL	NCT00991211	Completed; final results presented at ASH 09	B + R superior to R-CHOP for CR and PFS
Single-agent pixantrone dimaleate versus investigator’s choice therapy [49]	Third-line treatment of R/R aggressive NHL	NCT00088530 EXTEND (PIX301)	Completed; final results presented at ASH 10	Pixantrone superior to other single-agent therapies
Pixantrone + R versus gemcitabine + R	R/R DLBCL patients not eligible for SCT	NCT01321541 PIX-R (PIX306)	Recruiting	NA